DM
JBIO

Deerfield Management’s Jade Biosciences JBIO Stock Holding History

Deerfield Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-531,163
Closed -$4.58M – 152
2025
Q3 		$4.58M Hold
531,163
– – 0.07% 73
2025
Q2 		$5.31M Buy
+531,163
New +$18.1M 0.1% 74
2024
Q4 		– Sell
-40,332
Closed -$2.95M – 144
2024
Q3 		$2.95M Hold
40,332
– – 0.04% 76
2024
Q2 		$2.34M Buy
+40,332
New +$26.7M 0.04% 77
2021
Q4 		– Sell
-20,408
Closed -$15M – 130
2021
Q3 		$15M Hold
20,408
– – 0.29% 81
2021
Q2 		$16.3M Buy
+20,408
New +$16.3M 0.29% 91

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Deerfield Management's JBIO Position: Q4 2025 in Review

Deerfield Management sold out of Jade Biosciences (JBIO) in Q4 2025, closing a stake of 531,163 shares — an estimated $4.58M sold.

Deerfield Management first reported a position in JBIO in Q2 2021 and held it in 6 quarters. The position peaked at $16.3M in Q2 2021. 105 funds tracked by Wall St. Rank hold JBIO as of Q4 2025.

  • Deerfield Management reported no remaining Jade Biosciences position as of Q4 2025 after selling out during the quarter.
  • Deerfield Management sold 531,163 Jade Biosciences shares in Q4 2025, an estimated $4.58M.
  • Deerfield Management first reported a position in Jade Biosciences in Q2 2021 and held it in 6 quarters.
  • Deerfield Management's Jade Biosciences position peaked at $16.3M in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2025.

Based on Deerfield Management's 13F filing for Q4 2025, filed 17 Feb 2026.